Global Proteomics Market to Reach $6.1 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on Proteomics market. The global proteomics market is projected to reach $6.1 billion by the year 2015, driven by increasing adoption in life sciences research in both developed and emerging markets. The shift towards proteomics from genomics facilitates technological advancements, which are aimed at providing assistance to drug discovery researchers by offering enhanced throughput, resolution, and sensitivity, compared to conventional protein research tools.

Proteomics: A Global Strategic Business Report

Proteomics has become the spotlight for pharmaceutical and biotechnology companies, offering new avenues to precision medication and customized diagnosis and treatment. In the post genomic era, proteomics technologies are expected to play a crucial part in the fields of medicine, molecular diagnostics, and drug discovery. Some of the most commonly employed technologies include protein analysis by mass spectrometry and 2D gel electrophoresis for separation of proteins. In the field of medicine, proteomics are expected to benefit from the personalization of medicine as well as from the combination of diagnostics and therapeutics. In the overall proteomic technologies market, protein biochip and bioinformatics technologies are expected to witness the maximum expansion and development, while neurological disorders and cancer are likely to emerge as the key application areas.

Though the life sciences industry has remained largely unaffected by the global economic meltdown, the collapse of the capital market is proving detrimental to several sectors of the biotechnology market that is heavily reliant on public and private funding. The slow pace of capital market recovery, particularly with regard to private equity and venture capital, is expected to affect the pattern of growth in the biotechnology segment. A key legacy of the recession is the blurring distinction between pharma and biotech companies, with more and more players from the pharma sector making aggressive expansion efforts into large molecule research arena – earlier a prerogative of the biotech sector. A potential growth opportunity for biotech companies emerges from the launch of personalized medicine, which enables companies to forge alliances with pharma majors who lack expertise in this field.

The United States and Europe represent the predominant markets, as stated by the new market research report on Proteomics. The shift towards proteomics from genomics facilitates technological advancements, which are aimed at providing assistance to drug discovery researchers by offering enhanced throughput, resolution, and sensitivity, compared to conventional protein research tools. In addition, increased funding for research and sustained pharmaceutical and biotechnology industry interest in drug discovery is another growth factor. Though proteomics is a critical technology for mass screening and post-translational modification of proteins, industry’s progress is restricted by complications faced by organizations in sourcing adequate funding for various research initiatives. The high cost of equipment and software further enhances the significance of funding.

The US proteomics market benefits from the vast diversity and scale of operations of the academic sector. Further, ability of academics to reposition themselves into new groups in order to meet the scientific challenges in proteomics industry also proves beneficial for the industry. Proteomics research, being complementary to genomic approaches, has been witnessing increased integration with drug discovery market. Rising interest in integrated technologies is driving rapid expansion of bio-informatics and protein biochip technologies in Europe.

Major players profiled in the report include Agilent Technologies, Bio-Rad Laboratories, Bruker Daltonics Inc., Dionex Corporation, GE Healthcare, Human Genome Sciences Inc., Life Technologies Corporation, Millipore Corp., PerkinElmer, Proteome Systems Ltd., Shimadzu Biotech, and Thermo Fisher Scientific.

The report titled “Proteomics: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a review of market trends, product introductions/innovations, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including the United States, Canada, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit – http://www.strategyr.com/Proteomics_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media